To hear about similar clinical trials, please enter your email below
Trial Title:
Predictive Value of Pet Scan With Fdg Performed During Irradiation in Patients Treated for Oesaphagus Carcinoma
NCT ID:
NCT00934505
Condition:
Oesophageal Cancer
Conditions: Keywords:
Positron-Emission Tomography
PET Scan
FDG
oesophageal cancer
chemo-Radiation Oncology
SUV
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Prospective
Summary:
The poor prognosis in the early-stage of oesophageal carcinoma cancer is due to potential
worsening of the disease (local relapse, metastasis), to insufficient efficacy and
toxicity of actual treatments.
FDG-PET is a medical imaging modality allowing the quantification of the tumour glucose
consumption. Then, this exam is used for pathology staging, target volume definition for
RT, and treatment efficiency few months after CRT. Our assumption is that an FDG-PET exam
during the course of CRT might be predictive of the treatment efficiency few months
later.
In this study, we propose to perform 4 FDG-PET: first "PET1" before chemo-radiotherapy,
second "PET2" during the chemo-radiotherapy (see RTEP1), third and fourth "PET3" "PET4"
3month and 12 month after the end of radiotherapy.
We will investigate the performances of FDG-PET performed during CRT for the prediction
of the one-year patient heath outcome. If the predictive value of TEP2 is confirmed, we
would be able to optimize the planning treatment during the course of the therapy.
Criteria for eligibility:
Study pop:
Diagnosed patients a carcinoma of the oesophagus histologiquement proved
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Carcinoma épidermoïde of the oesophagus histologically proved, UICC Stage II B, III
or IVa (TNM on 2002)
- Decision of treatment by radio concomitant chemotherapy (radiotherapy in classic
spreading of 50Gy associated with a platinum chemotherapy.
Exclusion Criteria:
- Presence of a second evolutionary cancer in the previous three years
- index of performance OMS > 2
- Patients badly balanced diabetics
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
CLCC H.Becquerel
Address:
City:
Rouen
Zip:
76000
Country:
France
Status:
Recruiting
Contact:
Last name:
THILLAYS Marc, RT
Phone:
0033232082497
Email:
marc.thillays@touen.fnclcc.fr
Contact backup:
Last name:
GOUEL Pierrick, RT
Phone:
0033232082497
Email:
pierrick.gouel@rouen.fnclcc.fr
Investigator:
Last name:
BENYOUCEF Ahmed, MD
Email:
Sub-Investigator
Start date:
May 2009
Completion date:
April 2014
Lead sponsor:
Agency:
Centre Henri Becquerel
Agency class:
Other
Source:
Centre Henri Becquerel
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT00934505
